Claims for Patent: 5,387,612

Summary for Patent: 5,387,612

Title:	Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for treating Parkinson's disease
Abstract:	R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.
Inventor(s):	Youdim; Mussa B. H. (Haifa, IL), Finberg; John P. M. (Tivon, IL), Levy; Ruth (Tel-Aviv, IL), Sterling; Jeffrey (Jerusalem, IL), Lerner; David (Jerusalem, IL), Berger-Paskin; Tirtsah (Raanana, IL), Yellin; Haim (Ramat-Gan, IL)
Assignee:	Teva Pharmaceutical Industries Ltd. (Jerusalem, IL) Technion Research and Development Foundation Ltd. (Haifa, IL)
Application Number:	08/063,455
Patent Claims:	1. A method of treating as subject for Parkinson's disease which consists essentially of administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof effective to treat the subject. 2. The method of claim 1, wherein R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof is administered orally. 3. The method of claim 1, wherein R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof is administered rectally. 4. The method of claim 1, wherein R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof is administered transdermally. 5. The method of claims 2, 3, or 4, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 2 to 20 mg per daily dosage unit. 6. The method of claims 2, 3, or 4, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 5 to 10 mg per daily dosage unit. 7. The method of claim 1, wherein R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof is administered parenterally. 8. The method of claim 7, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 1 to 10 mg per mL per daily dosage unit. 9. The method of claim 8, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 2 to 5 mg per mL per daily dosage unit.